Top 30 Oncology Drugs Manufacturers 2019

がん治療薬製造のトップ30社2019

◆タイトル:Top 30 Oncology Drugs Manufacturers 2019
◆商品コード:VGN906181
◆調査・発行会社:visiongain
◆発行日:2019年5月
◆ページ数:157
◆レポート形式:PDF / 英語
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆産業分野:産業未分類
◆販売価格オプション(消費税別)
Sigle User(1名様閲覧用)GBP2,699 ⇒換算¥377,860見積依頼/購入/質問フォーム
Five User(5名様閲覧用)GBP2,999 ⇒換算¥419,860見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)GBP4,999 ⇒換算¥699,860見積依頼/購入/質問フォーム
※Single UserとDept Licence(Five User)の場合、DRM(デジタル著作権管理)付PDFファイルです。認証されたPC上のみでの閲覧と、PDF閲覧期限は購入日より1年となります。Dept Licence(Five User)は印刷できますが、Single Userは印刷できません。Site Licence/Global Site Licenseの場合は、閲覧・印刷制限はありません。
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はvisiongainの日本における正規販売代理店です。

【レポートの概要】

本調査レポートでは、"がん治療薬製造のトップ30社2019"について調査・分析し、レポートサマリー、市場動向、主要国別市場分析、市場環境分析、主要企業分析などの情報をお届けいたします。

Cancer treating drugs market forms the most lucrative sector in pharmaceuticals. As the ageing population continues to rise across the world, the incidence of cancer will continue to grow, leading to increased spending on cancer-treating medicines. This report lists and discusses the top 30 oncology drugs manufacturers.How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.
In this brand new 157-page report you will receive 83 tables and 64 figures–all unavailable elsewhere.
The 157-page report provides clear detailed insight into the top 30 oncology drugs manufacturers. Discover the key drivers and challenges affecting the market.
By ordering and reading our brand-new report today you stay better informed and ready to act.
Report Scope
• Assessment of the leading companies in the global oncology drugs market. The list below shows some of the companies that are discussed in the report:
• Abbott Laboratories
• AbbVie
• Amgen
• Astellas Pharma
• AstraZeneca
• Aurora Biophama
• Boehringer Ingelheim
• Bristol-Myers Squibb (BMS)
• Celgene Corporation
• Eli Lilly
• Fresenius Kabi
• Gilead
• GlaxoSmithKline (GSK)
• Grifols
• Johnson & Johnson
• Jounce Therapeutics
• Other companies

• For each company, the report provides information and discussion on:
• Company overview
• Product portfolio
• Recent development
• Financial information
• Key questions answered by this report:
• How is the Oncology Drugs Manufacturers market evolving?
• What is driving and restraining the Oncology Drugs Manufacturers market?
• What will be the main driver for the overall market?
• Will leading Oncology Drugs Manufacturers broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
• Who are the leading players and what are their prospects over the forecast period?
Visiongain’s study is intended for anyone requiring commercial analyses for the Top 30 Oncology Drugs Manufacturers 2019. You find data, trends and predictions.
Buy our report today Top 30 Oncology Drugs Manufacturers 2019: AstraZeneca, Merck, Novartis, Amgen, GlaxoSmithKline, Johnson & Johnson, Roche, Pfizer, Eli Lilly, Other Companies.

【レポートの目次】

1 Report Overview
1.1 Global Cancer-Treating drugs Overview
1.2 Research Methodology
1.3 Primary Research
1.4 Secondary Research
1.5 Why You Should Read This Report
1.6 Who is This Report For?
1.7 Associated Visiongain Reports
1.8 About Visiongain

2 Introduction to Cancer-Treating Drugs
2.1 The Physiology of Cancer – Causes and Effects
2.2 Uncontrolled Growth
2.3 Dedifferentiation
2.4 Invasiveness and Metastasis
2.5 Causes of Cancer
2.6 The Incidence and Prevalence of Cancer – Trends in the World
2.7 Incidence
2.8 Mortality
2.9 Survival – Improving Odds
2.10 The Developed World
2.11 Treating Tumours – How Can We Fight Back?
2.12 Chemotherapy – The Traditional Treatment
2.13 Hormone Therapies
2.14 Immunotherapy – A Magic Bullet?
2.14.1 Monoclonal Antibodies (mAbs)
2.14.2 Cancer Vaccines
2.14.3 Non-Specific Immunotherapies
2.14.4 Targeted Therapies
2.14.5 Differentiating Agents

3 Cancer Treating Drugs Market, Qualitative Analysis
3.1 SWOT Analysis of the Anti-Cancer Drugs Market
3.1.1 Strengths of the Market
3.1.1.1 The Rising Incidence of Cancer
3.1.1.2 Ample Treatment Options Available
3.1.2 Weaknesses
3.1.2.1 The Challenges of Drug Development
3.1.2.2 The Complex Nature of Cancer
3.1.3 Opportunities in the Anti-Cancer Drugs Market
3.1.3.1 The Advancement of Research
3.1.3.2 A Shift Towards Personalisation
3.1.4 Threats Facing the Anti-Cancer Drugs Market
3.1.4.1 The Threat of Regulation
3.2 STEP Analysis of the Anti-Cancer Drugs Market
3.2.1 Social Factors: The Cost of Living Longer
3.2.2 Technological Developments: Making the Market Move Forward
3.2.3 Economic Pressure: Treatment’s Hefty Price Tag
3.2.4 Political Issues: Governmental Involvement in Treatment

4 Leading Companies in Cancer Treating Drugs Market
4.1 AstraZeneca Plc
4.1.1 AstraZeneca Plc: Company Overview
4.1.2 AstraZeneca Plc: Product Portfolio
4.1.3 AstraZeneca Plc: Recent Developments
4.2 Merck & Co. Inc.
4.2.1 Merck & Co. Inc.: Company Overview
4.2.2 Merck & Co. Inc.: Product Portfolio
4.3.1 Merck & Co. Inc.: Recent Developments
4.3 Novartis AG
4.3.1 Novartis AG: Company Overview
4.3.2 Novartis AG: Product Portfolio
4.3.3 Novartis AG: Recent Developments
4.4 Amgen Inc.
4.4.1 Amgen Inc.: Company Overview
4.4.2 Amgen Inc.: Product Portfolio
4.4.3 Amgen Inc.: Recent Developments
4.5 BRISTOL-MYERS SQUIBB
4.5.1 BRISTOL-MYERS SQUIBB: Company Overview
4.5.2 BRISTOL-MYERS SQUIBB: Product Portfolio
4.5.3 BRISTOL-MYERS SQUIBB: Recent Developments
4.6 GlaxoSmithKline PLC (GSK Consumer Care)
4.6.1 GlaxoSmithKline PLC: Company Overview
4.6.1 GlaxoSmithKline PLC: Product Portfolio
4.6.2 GlaxoSmithKline PLC: Recent Developments
4.7 Johnson & Johnson
4.7.1 Johnson & Johnson: Company Overview
4.7.2 Johnson & Johnson: Product Portfolio
4.7.3 Johnson & Johnson: Recent Developments
4.8 F. HOFFMANN-LA ROCHE AG
4.8.1 F. Hoffmann-La Roche: Company Overview
4.8.2 F. Hoffmann-La Roche: Product Portfolio
4.8.3 F. Hoffmann-La Roche: Recent Developments
4.9 Eli Lilly and Company
4.9.1 Eli Lilly and Company: Company Overview
4.9.2 Eli Lilly and Company: Product Portfolio
4.9.3 Eli Lilly and Company: Recent Developments
4.10 Celgene Corporation
4.10.1 Celgene Corporation: Company Overview
4.10.2 Celgene Corporation: Product Portfolio
4.10.3 Celgene Corporation: Recent Developments
4.11 Pfizer Inc.
4.11.1 Pfizer Inc.: Company Overview
4.11.2 Pfizer Inc.: Product Portfolio
4.11.3 Pfizer: Recent Developments
4.12 Astellas Pharma, Inc.
4.12.1 Astellas Pharma, Inc.: Company Overview
4.12.2 Astellas Pharma, Inc.: Recent Development
4.13 Abbott Laboratories Inc.
4.13.1 Abbott Laboratories Inc.: Company Overview
4.13.2 Abbott Laboratories Inc.: Product Portfolio
4.13.3 Abbott Laboratories Inc.: Recent Development
4.14 AbbVie Inc.
4.14.1 AbbVie Inc.: Company Overview
4.14.2 AbbVie Inc.: Product Portfolio
4.14.3 AbbVie: Recent Development
4.15 Sanofi S.A. (Sanofi Genzyme)
4.15.1 Sanofi S.A.: Company Overview
4.15.2 Sanofi S.A.: Product Portfolio
4.15.3 Sanofi S.A.: Recent Development
4.16 Takeda Pharmaceutical Company Ltd.
4.16.1 Takeda Pharmaceutical Company Ltd.: Company Overview
4.16.2 Takeda Pharmaceutical Company Ltd.: Product Portfolio
4.16.3 Takeda Pharmaceutical Company Ltd.: Recent Developments
4.17 Gilead Science, Inc.
4.17.1 Gilead Science, Inc.: Company Overview
4.17.2 Gilead Science, Inc.: Product Portfolio
4.17.3 Gilead Science, Inc.: Recent Developments
4.18 A. Menarini Industrie Farmaceutiche Riunite Srl
4.18.1 A. Menarini Industrie Farmaceutiche Riunite Srl: Company Overview
4.18.2 A. Menarini Industrie Farmaceutiche Riunite Srl: Recent Developments
4.19 FRESENIUS KABI AG
4.19.1 FRESENIUS KABI AG: Product Portfolio
4.19.2 FRESENIUS KABI AG: Recent Developments
4.20 GRIFOLS S.A.
4.21 Boehringer Ingelheim GMBH
4.21.1 Boehringer Ingelheim GMBH: Company Overview
4.21.2 Boehringer Ingelheim GMBH: Product Portfolio
4.21.3 Boehringer Ingelheim GMBH: Recent Developments
4.22 Sun Pharmaceutical Industries Ltd.
4.22.1 Sun Pharmaceutical Industries Ltd.: Company Overview
4.22.2 Sun Pharmaceutical Industries Ltd.: Product Portfolio
4.22.3 Sun Pharmaceutical Industries Ltd.: Recent Developments
4.23 Teva Pharmaceutical Industries Ltd.
4.23.1 Teva Pharmaceutical Industries Ltd.: Company Overview
4.23.2 Teva Pharmaceutical Industries Ltd.: Product Portfolio
4.23.3 Teva Pharmaceutical Industries Ltd.: Recent Developments
4.24 Valeant Pharmaceuticals International, Inc.
4.24.1 Valeant Pharmaceuticals International, Inc.: Company Overview
4.24.2 Valeant Pharmaceuticals International, Inc.: Product Portfolio
4.24.3 Valeant Pharmaceuticals International, Inc.: Recent Developments
4.25 ZIOPHARM Oncology, Inc.
4.25.1 ZIOPHARM Oncology, Inc.: Company Overview
4.26 Sorrento Therapeutics, Inc.
4.26.1 Sorrento Therapeutics, Inc.: Company Overview
4.26.2 Sorrento Therapeutics, Inc.: Recent Developments
4.27 Aurora Biopharma, Inc.
4.27.1 Aurora Biopharma, Inc.: Company Overview
4.28 Tessa Therapeutics Pte Ltd.
4.28.1 Tessa Therapeutics Pte Ltd.: Company Overview
4.28.2 Tessa Therapeutics Pte Ltd.: Recent Developments
4.29 Jounce Therapeutics, Inc.
4.29.1 Jounce Therapeutics, Inc.: Company Overview
4.29.2 Jounce Therapeutics, Inc.: Recent Developments
4.30 Mylan N.V.
4.30.1 Mylan N.V.: Company Overview
4.30.1 Mylan N.V.: Recent Developments

Appendices
Associated Visiongain Reports
Visiongain Report Sales Order Form
Appendix A
About Visiongain
Appendix B
Visiongain report evaluation form

List of Tables
Table 2.1 Cancer-Treating Agents: Chemotherapies and Hormone Therapies, 2017
Table 2.2 Cancer-Treating Agents: Immunotherapies, Targeted Therapies and Differentiating Agents, 2017
Table 3.1 Strengths, Weaknesses, Opportunities and Threats in the Anti-Cancer Drugs Market
Table 3.2 Social, Technological, Economic and Political Analysis of the Anti-Cancer Drugs Market, 2017
Table 4.1 AstraZeneca Plc: Company Overview
Table 4.2 AstraZeneca Plc: Product Portfolio
Table 4.3 AstraZeneca Plc: Recent Developments
Table 4.4 Merck & Co. Inc.: Company Overview
Table 4.5 Merck & Co. Inc.: Product Portfolio
Table 4.6 Merck & Co. Inc.: Recent Developments
Table 4.7 Novartis AG: Company Overview
Table 4.8 Novartis AG: Product Portfolio
Table 4.9 Novartis AG: Recent Developments
Table 4.10 Amgen Inc.: Company Overview
Table 4.11 Amgen Inc.: Product Portfolio
Table 4.12 Amgen Inc.: Recent Developments
Table 4.13 BRISTOL-MYERS SQUIBB: Company Overview
Table 4.14 BRISTOL-MYERS SQUIBB: Product Portfolio
Table 4.15 BRISTOL-MYERS SQUIBB: Recent Developments
Table 4.16 GlaxoSmithKline PLC: Company Overview
Table 4.17 GlaxoSmithKline PLC: Product Portfolio
Table 4.18 GlaxoSmithKline PLC: Recent Developments
Table 4.19 Johnson & Johnson: Company Overview
Table 4.20 Johnson & Johnson: Product Portfolio
Table 4.21 Johnson & Johnson: Recent Developments
Table 4.22 F. Hoffmann-La Roche: Company Overview
Table 4.23 F. Hoffmann-La Roche: Product Portfolio
Table 4.24 F. Hoffmann-La Roche: Recent Developments
Table 4.25 Eli Lilly and Company: Company Overview
Table 4.26 Eli Lilly and Company: Product Portfolio
Table 4.27 Eli Lilly and Company: Recent Developments
Table 4.28 Celgene Corporation: Company Overview
Table 4.29 Celgene Corporation: Product Portfolio
Table 4.30 Celgene Corporation: Recent Developments
Table 4.31 Pfizer Inc.: Company Overview
Table 4.32 Pfizer Inc.: Product Portfolio
Table 4.33 Pfizer: Recent Developments
Table 4.34 Astellas Pharma, Inc.: Company Overview
Table 4.35 Astellas Pharma, Inc.: Recent Developments
Table 4.36 Abbott Laboratories Inc.: Company Overview
Table 4.37 Abbott Laboratories Inc.: Product Portfolio
Table 4.38 Abbott Laboratories Inc.: Recent Developments
Table 4.39 AbbVie Inc.: Company Overview
Table 4.40 AbbVie Inc.: Product Portfolio
Table 4.41 AbbVie Inc.: Recent Developments
Table 4.42 Sanofi S.A.: Company Overview
Table 4.43 Sanofi S.A.: Product Portfolio
Table 4.44 Sanofi S.A.: Recent Developments
Table 4.45 Takeda Pharmaceutical Company Ltd.: Company Overview
Table 4.46 Takeda Pharmaceutical Company Ltd.: Product Portfolio
Table 4.47 Takeda Pharmaceutical Company Ltd.: Recent Developments
Table 4.48 Gilead Science, Inc.: Company Overview
Table 4.49 Gilead Science, Inc.: Product Portfolio
Table 4.50 Gilead Science, Inc.: Recent Developments
Table 4.51 A. Menarini Industrie Farmaceutiche Riunite Srl : Company Overview
Table 4.52 A. Menarini Industrie Farmaceutiche Riunite Srl : Recent Developments
Table 4.53 FRESENIUS KABI AG: Company Overview
Table 4.54 FRESENIUS KABI AG: Product Portfolio
Table 4.55 FRESENIUS KABI AG: Recent Developments
Table 4.56 Grifols S.A.: Company Overview
Table 4.57 Grifols S.A.: Product Portfolio
Table 4.58 Boehringer Ingelheim GMBH: Company Overview
Table 4.59 Boehringer Ingelheim GMBH: Product Portfolio
Table 4.60 Boehringer Ingelheim GMBH: Recent Developments
Table 4.61 Sun Pharmaceutical Industries Ltd.: Company Overview
Table 4.62 Sun Pharmaceutical Industries Ltd.: Product Portfolio
Table 4.63 Sun Pharmaceutical Industries Ltd.: Recent Developments
Table 4.64 Teva Pharmaceutical Industries Ltd.: Company Overview
Table 4.65 Teva Pharmaceutical Industries Ltd.: Product Portfolio
Table 4.66 Teva Pharmaceutical Industries Ltd.: Recent Developments
Table 4.67 Valeant Pharmaceuticals International, Inc.: Company Overview
Table 4.68 Valeant Pharmaceuticals International, Inc.: Product Portfolio
Table 4.69 Valeant Pharmaceuticals International, Inc.: Recent Developments
Table 4.70 ZIOPHARM Oncology, Inc.: Company Overview
Table 4.71 Sorrento Therapeutics, Inc.: Company Overview
Table 4.72 Sorrento Therapeutics, Inc.: Recent Developments
Table 4.73 Aurora Biopharma, Inc.: Company Overview
Table 4.74 Tessa Therapeutics Pte Ltd.: Company Overview
Table 4.75 Tessa Therapeutics Pte Ltd.: Recent Developments
Table 4.76 Jounce Therapeutics, Inc.: Company Overview
Table 4.77 Valeant Pharmaceuticals International, Inc.: Recent Developments
Table 4.78 Mylan N.V.: Company Overview
Table 4.79 Mylan N.V.: Recent Developments

List of Figures
Figure 4.1 AstraZeneca Plc: Revenue, ($million), 2013-2017
Figure 4.2 AstraZeneca Plc: Product Segments Share (%), 2017
Figure 4.3 AstraZeneca Plc: Geographic Share (%), 2017
Figure 4.4 Merck & Co. Inc.: Revenue, ($million), 2013-2017
Figure 4.5 Merck & Co. Inc., Product Segments Share (%), 2017
Figure 4.6 Merck & Co. Inc., Geographical Presence Share (%), 2017
Figure 4.7 Novartis AG: Revenue, ($million), 2013-2017
Figure 4.8 Novartis AG, Product Segments Share (%), 2017
Figure 4.9 Novartis AG: Geographical Presence Share (%), 2017
Figure 4.10 Amgen Inc., Revenue, ($million), 2013-2017
Figure 4.11 Amgen Inc., Product Segments Share (%), 2017
Figure 4.12 Amgen Inc.: Geographical Presence Share (%), 2017
Figure 4.13 BRISTOL-MYERS SQUIBB: Revenue, ($million), 2013-2017
Figure 4.14 BRISTOL-MYERS SQUIBB: Product Segments Share (%), 2017
Figure 4.15 BRISTOL-MYERS SQUIBB: Geographical Presence Share (%), 2017
Figure 4.16 GlaxoSmithKline PLC: Revenue, ($million), 2013-2017
Figure 4.17 GlaxoSmithKline PLC: Product Segments Share (%), 2017
Figure 4.18 GlaxoSmithKline PLC: Geographical Presence Share (%), 2017
Figure 4.19 Johnson & Johnson: Revenue, ($million), 2013-2017
Figure 4.20 Johnson & Johnson: Product Segments Share (%), 2017
Figure 4.21 Johnson & Johnson: Geographical Presence Share (%), 2017
Figure 4.22 F. Hoffmann-La Roche: Revenue, ($million), 2013-2017
Figure 4.23 F. Hoffmann-La Roche: Product Segments Share (%), 2017
Figure 4.24 F. Hoffmann-La Roche, Geographical Presence Share (%), 2017
Figure 4.25 Eli Lilly and Company: Revenue, ($million), 2013-2017
Figure 4.26 Eli Lilly and Company: Product Segments Share (%), 2017
Figure 4.27 Eli Lilly and Company: Geographical Presence Share (%), 2017
Figure 4.28 Celgene Corporation, Revenue, ($million), 2013-2017
Figure 4.29 Pfizer Inc.: Revenue, ($million), 2013-2017
Figure 4.30 Pfizer Inc.: Product Segments Share (%), 2017
Figure 4.31 Pfizer Inc., Geographical Presence Share (%), 2017
Figure 4.32 Astellas Pharma, Inc.: Revenue, ($million), 2013-2017
Figure 4.33 Astellas Pharma, Inc.: Geographical Presence Share (%), 2017
Figure 4.34 Abbott Laboratories Inc.: Revenue, ($million), 2013-2017
Figure 4.35 Abbott Laboratories Inc.: Product Segment Share (%), 2017
Figure 4.36 Abbott Laboratories Inc., Geographic Presence Share (%), 2017
Figure 4.37 AbbVie Inc.: Revenue, ($million), 2013-2017
Figure 4.38 AbbVie Inc.: Product Segments Share (%), 2017
Figure 4.39 AbbVie Inc.: Geographical Presence Share (%), 2017
Figure 4.40 Sanofi S.A.: Revenue, ($million), 2013-2017
Figure 4.41 Sanofi S.A.: Product Segments Share (%), 2017
Figure 4.42 Sanofi S.A., Geographical Presence Share (%), 2017
Figure 4.43 Takeda Pharmaceutical Company Ltd., Revenue, ($million), 2014-2018
Figure 4.44 Takeda Pharmaceuticals Inc., Geographical Presence Share (%), 2018
Figure 4.45 Gilead Science, Inc.: Revenue, ($million), 2013-2017
Figure 4.46 Gilead Science, Inc., Product Segments Share (%), 2017
Figure 4.47 Gilead Science, Inc., Geographical Presence Share (%), 2017
Figure 4.48 Grifols S.A.: Revenue, ($million), 2013-2017
Figure 4.49 Grifols S.A., Product Segments Share (%), 2017
Figure 4.50 Grifols S.A., Geographical Presence Share (%), 2017
Figure 4.51 Boehringer Ingelheim GMBH, Revenue, ($million), 2013-2017
Figure 4.52 Boehringer Ingelheim GMBH, Product Segments Share (%), 2017
Figure 4.53 Boehringer Ingelheim GMBH, Geographical Presence Share (%), 2017
Figure 4.54 Sun Pharmaceutical Industries Ltd., Revenue, ($million), 2014-2018
Figure 4.55 Teva Pharmaceutical Industries Ltd.: Revenue, ($million), 2013-2017
Figure 4.56 Teva Pharmaceutical Industries Ltd.: Product Segments Share (%), 2017
Figure 4.57 Teva Pharmaceutical Industries Ltd., Geographical Presence Share (%), 2017
Figure 4.58 Valeant Pharmaceuticals International, Inc.: Revenue, ($million), 2013-2017
Figure 4.59 Valeant Pharmaceuticals International, Inc.: Product Segments Share (%), 2017
Figure 4.60 Valeant Pharmaceuticals International, Inc.: Geographical Presence Share (%), 2017
Figure 4.61 ZIOPHARM Oncology, Inc., Revenue, ($million), 2013-2017
Figure 4.62 Jounce Therapeutics, Inc.: Revenue, ($million), 2016-2017
Figure 4.63 Mylan N.V., Revenue, ($million), 2013-2017
Figure 4.64 Mylan N.V., Geographical Presence Share (%), 2017

★調査レポート[がん治療薬製造のトップ30社2019] ( Top 30 Oncology Drugs Manufacturers 2019 / VGN906181) 販売に関する免責事項
[がん治療薬製造のトップ30社2019] ( Top 30 Oncology Drugs Manufacturers 2019 / VGN906181) についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆